Porous silica material for use as a pharmaceutical or dietary active ingredient
AssigneeSigrid Therapeutics AB
InventorsRobert Csikasz, Tore Bengtsson, Natalia Kupferschmidt, Alfonso E. Garcia-Bennett
Life of this patent
Estimating the term…
Abstract
A porous silica material for use as a pharmaceutical or dietary active ingredient having pores in the mesoscale range (2-50 nm), wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
Claims25
1-18. (canceled)
A method of the prophylaxis or treatment of:
- metabolic syndrome, type 2 diabetes, insulin resistance, or hyperglycemia in a human or animal in need thereof, comprising administering to the human or animal an effective amount of a porous silica material having pores in the mesoscale range of 2-50 nm, wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
A method of lowering glucose levels in the blood in a human or animal in need thereof, comprising administering to the human or animal an effective amount of a porous silica material having pores in the mesoscale range of 2-50 nm, wherein the average pore size of the pores in the mesoscale range is in the range of 2 to 25 nm, and the pore size distribution (PSD) in the mesoscale range is such that at least 80% of the pores fall within the range of 2 to 25 nm.
Dependencies are inferred from the claim text.